Prostate cancer is a disease that mainly affects men over the age of 55 and the numbers of men diagnosed has increased due to the ageing population. Public Health England ran a Be Clear on Cancer local pilot campaign to raise awareness of the increased risk of prostate cancer amongst black men in six London boroughs in 2014. NHS England continues to support effective new treatments and diagnostics and implement the ambitious independent Cancer Taskforce strategy and is working closely with leading clinical experts and Prostate Cancer UK to bring the latest research on this disease into practice. Targeted work is also being undertaken to ensure prostate cancer is diagnosed quickly and that everyone receives the best care wherever they live across the country.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-03-07T10:25:38.58Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prostate Cancer"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps the Government is taking to (a) raise awareness and (b) reduce the prevalence of prostate cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"} } , "tablingMemberConstituency" : {"_value" : "Leicester South"} , "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"} ], "uin" : "130191"} , {"_about" : "http://data.parliament.uk/resources/850994", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/850994/answer", "answerText" : {"_value" : "
The United Kingdom National Screening Committee (UK NSC) last reviewed the evidence about screening for prostate cancer in 2016. Evidence showed that prostate screening can reduce prostate cancer deaths by 27% of the 10,000 lives lost in the UK annually to prostate cancer. No assessment has been made on the potential number of cases identified earlier by a screening programme.<\/p>
The Committee recommended against a population screening programme. The reasons for this included that the test which is available for use in screening, Prostate-Specific Antigen (PSA), is neither very specific nor very sensitive, and is unable to distinguish between slow-growing and fast-growing cancers; there is therefore a risk that a national screening programme would lead to a high number of false positives. There are major harms of treating men who incorrectly test positive (i.e. have false positive tests), these include impotence, incontinence and rectal problems.<\/p>
The UK NSC will be reviewing the evidence to screen for prostate cancer later in 2018/19. More information will be available at:<\/p>
https://legacyscreening.phe.org.uk/prostatecancer<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-07T10:10:59.113Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prostate Cancer: Screening"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of (a) the potential number of cases of prostate cancer which could be identified earlier by a national prostate cancer screening programme and (b) the potential effect such a programme on survival rates.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "130192"}
, {"_about" : "http://data.parliament.uk/resources/850995", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/850995/answer", "answerText" : {"_value" : " National Health Service services for pancreatic cancer have been significantly improved in recent years. This includes clearer diagnostic pathways; decision making by specialist multi-disciplinary teams; and the centralisation of pancreas surgery within specialist teams.<\/p> The Five Year Forward View \u2018Next Steps\u2019 Plan is available at:<\/p> https://www.england.nhs.uk/five-year-forward-view/<\/a><\/p> This now aims to further improve cancer survival by an extra 5,000 people and improve experience of care over the next two years, with a range of improvements including:<\/p> - Patients having better access to the latest treatments, with roll-out of the largest radiotherapy upgrade programme in 15 years, with an extra £94 million to be spent on equipping hospitals with state of the art linear accelerators;<\/p> - Patients being tested sooner with investment in greater diagnostic capacity, including 10 new Rapid Diagnostic and Assessment Centres. This will be measured through the new 28 day faster diagnosis standard which will be rolled out from April 2018; and<\/p> - Personalised care and support being offered to patients during treatment and for those recovering from cancer, improving their quality of life and experience of care.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-07T10:24:01.197Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prostate Cancer: Mortality Rates"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve pancreatic cancer survival rates.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "130193"}
, {"_about" : "http://data.parliament.uk/resources/850997", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/850997/answer", "answerText" : {"_value" : " No such discussions have taken place.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-07T10:27:43.447Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with the devolved Administrations on the future treatment and care of people with cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "130194"}
, {"_about" : "http://data.parliament.uk/resources/850998", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/850998/answer", "answerText" : {"_value" : " No such assessment has been made. \u200e In December 2017, the latest month for which figures are available, 94.9% of people were seen by a specialist within two weeks of an urgent general practitioner referral for suspected cancer.<\/p> Improving early diagnosis of cancer is a priority for this Government. We have committed to delivering the recommendations in the Independent Cancer Taskforce report, \u2018Achieving World-Class Cancer Outcomes: A strategy for England 2015-2020\u2019, including the new 28 day faster diagnosis standard. NHS England has also confirmed £200 million of transformation funding over the next two years, this includes encouraging local areas to find new and innovative ways to diagnose cancer earlier.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-07T10:22:36.343Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of the speed with which (a) GPs in the UK and (b) their equivalents in other countries refer patients who might have cancer; and what steps he is taking to improve the speed of cancer referrals.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "130195"}
, {"_about" : "http://data.parliament.uk/resources/851000", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/851000/answer", "answerText" : {"_value" : " Cancer is a priority for this Government and survival rates are at a record high1<\/sup>. Since 2010 rates of survival from cancer have increased year-on-year. Around 7,000 people are alive today who would not have been had mortality rates stayed the same as in 2010. But we know there is more to do, and NHS England is leading the health and care system in implementing the recommendations of the independent Cancer Taskforce report, \u2018Achieving World-Class Cancer Outcomes: A strategy for England 2015-2020\u2019, to save a further 30,000 lives a year by 2020.<\/p> <\/p> Note:<\/p> 1<\/sup>Between 2005 and 2013 one-year survival for all cancers combined increased from 63.6% to 70.2%. Between 2005 and 2009 five-year survival for all cancer combined increased from 46.2% to 49.6%.<\/p> Source: Office for National Statistics<\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-07T10:17:52.97Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Mortality Rates"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to increase cancer survival rates in the next five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "130197"}
, {"_about" : "http://data.parliament.uk/resources/851003", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/851003/answer", "answerText" : {"_value" : " Data is not available in the format requested.<\/p> NHS England publishes monthly performance data against the waiting times standards for diagnostic tests and the waiting times of people referred by their general practitioner with suspected cancer or breast symptoms and those subsequently diagnosed with and treated for cancer. This information is available at the following links:<\/p> <\/p> Drug<\/p><\/td> Number<\/p><\/td><\/tr> Atezolizumab<\/p><\/td> 34<\/p><\/td><\/tr> Bendamustine<\/p><\/td> 2,321<\/p><\/td><\/tr> Bevacizumab<\/p><\/td> 1,595<\/p><\/td><\/tr> Blinatumomab<\/p><\/td> 29<\/p><\/td><\/tr> Bortezomib<\/p><\/td> 105<\/p><\/td><\/tr> Bosutinib<\/p><\/td> 39<\/p><\/td><\/tr> Brentuximab<\/p><\/td> 346<\/p><\/td><\/tr> Cabozantinib<\/p><\/td> 154<\/p><\/td><\/tr> Carfilzomib<\/p><\/td> 45<\/p><\/td><\/tr> Ceritinib<\/p><\/td> 15<\/p><\/td><\/tr> Cetuximab<\/p><\/td> 1,708<\/p><\/td><\/tr> Clofarabine<\/p><\/td> 82<\/p><\/td><\/tr> Crizotinib<\/p><\/td> 127<\/p><\/td><\/tr> Daratumumab<\/p><\/td> 35<\/p><\/td><\/tr> Dasatinib<\/p><\/td> 107<\/p><\/td><\/tr> Eribulin<\/p><\/td> 347<\/p><\/td><\/tr> Everolimus<\/p><\/td> 370<\/p><\/td><\/tr> Ibrutinib<\/p><\/td> 1,067<\/p><\/td><\/tr> Ipilimumab/Nivolumab<\/p><\/td> 97<\/p><\/td><\/tr> Ixazomib<\/p><\/td> 119<\/p><\/td><\/tr> Lenvatinib<\/p><\/td> Fewer than 10<\/p><\/td><\/tr> Nab-paclitaxel<\/p><\/td> 134<\/p><\/td><\/tr> Nelarabine<\/p><\/td> 45<\/p><\/td><\/tr> Nivolumab<\/p><\/td> 541<\/p><\/td><\/tr> Obinutuzumab<\/p><\/td> 33<\/p><\/td><\/tr> Olaratumumab<\/p><\/td> 199<\/p><\/td><\/tr> Osimertinib<\/p><\/td> 255<\/p><\/td><\/tr> Palbociclib<\/p><\/td> 413<\/p><\/td><\/tr> Panitumumab<\/p><\/td> 392<\/p><\/td><\/tr> Pemetrexed<\/p><\/td> 37<\/p><\/td><\/tr> Pembrolizumab<\/p><\/td> 1,604<\/p><\/td><\/tr> Pertuzumab<\/p><\/td> 1,739<\/p><\/td><\/tr> Pegylated liposomal doxorubicin<\/p><\/td> 48<\/p><\/td><\/tr> Pomalidomide<\/p><\/td> 380<\/p><\/td><\/tr> Ponatinib<\/p><\/td> 88<\/p><\/td><\/tr> Radium-223 Dichloride<\/p><\/td> 243<\/p><\/td><\/tr> Regorafenib<\/p><\/td> 74<\/p><\/td><\/tr> Ribociclib<\/p><\/td> 29<\/p><\/td><\/tr> Sorafenib<\/p><\/td> 871<\/p><\/td><\/tr> Sunitinib<\/p><\/td> 71<\/p><\/td><\/tr> Talimogene laherparepvec<\/p><\/td> Fewer than 10<\/p><\/td><\/tr> Temsirolimus<\/p><\/td> Fewer than 10<\/p><\/td><\/tr> Trastuzumab Emtansine<\/p><\/td> 673<\/p><\/td><\/tr> Trametinib/Dabrafenib<\/p><\/td> 172<\/p><\/td><\/tr> Trifluridine and tipiracil<\/p><\/td> 444<\/p><\/td><\/tr> Vandetanib<\/p><\/td> 40<\/p><\/td><\/tr> Venetoclax<\/p><\/td> 118<\/p><\/td><\/tr> Vismodegib<\/p><\/td> 217<\/p><\/td><\/tr><\/tbody><\/table> Source: NHS England. Information provided from 31 July 2016 to end of January 2018 (latest data available).<\/p> <\/p> Note:<\/p> <\/p> Numbers lower than 10 are rounded-up to avoid releasing potentially patient identifiable data, as per NHS England\u2019s data protection commitments.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-07T16:51:57.227Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many patients have received medicine funded by the Cancer Drugs Fund by medicine since 2016.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "130200"}
, {"_about" : "http://data.parliament.uk/resources/851006", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/851006/answer", "answerText" : {"_value" : " No such discussions have taken place.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-07T10:28:29.91Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent discussions he has had with his counterpart in the Northern Ireland Government on the availability of drugs to treat cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "130201"}
, {"_about" : "http://data.parliament.uk/resources/851007", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/851007/answer", "answerText" : {"_value" : " The information is not available in the format requested.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-03-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-07T11:05:53.683Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mental Illness: Children"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many young people aged 17 and under were sectioned under the Mental Health Act 1983 by age in each of the last 10 years for which figures are available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "130202"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Jonathan+Ashworth&_page=1&max-date=2018-03-05", "page" : 0, "startIndex" : 1, "totalResults" : 849, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}